Compare BSAC & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSAC | PCVX |
|---|---|---|
| Founded | 1977 | 2013 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7B | 6.0B |
| IPO Year | 1994 | 2020 |
| Metric | BSAC | PCVX |
|---|---|---|
| Price | $31.15 | $47.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $29.50 | ★ $101.67 |
| AVG Volume (30 Days) | 295.7K | ★ 1.5M |
| Earning Date | 02-06-2026 | 11-04-2025 |
| Dividend Yield | ★ 3.17% | N/A |
| EPS Growth | ★ 42.15 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $2,434,135,287.00 | N/A |
| Revenue This Year | $41.02 | N/A |
| Revenue Next Year | $6.06 | N/A |
| P/E Ratio | $13.10 | ★ N/A |
| Revenue Growth | ★ 20.98 | N/A |
| 52 Week Low | $18.19 | $27.66 |
| 52 Week High | $31.38 | $93.77 |
| Indicator | BSAC | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 60.44 | 57.74 |
| Support Level | $29.53 | $42.40 |
| Resistance Level | $31.37 | $48.65 |
| Average True Range (ATR) | 0.58 | 1.75 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 75.12 | 84.82 |
Founded in 1978, Banco Santander Chile is part of Santander Group and majority-controlled by Santander Spain. It is the largest bank in Chile by loans and the second largest by deposits. The bank generates most of its net interest income (roughly 65% of total revenue) from its mortgages, unsecured consumer credit lines, and commercial loans. Banco Santander's commercial loan business is more focused on small- to medium-size companies, with firms generating more than CLP 10,000 million in revenue only making up around 5% of outstanding loans. Outside of lending, Banco Santander is the largest card issuer in the country with around 25% of the market and benefits from a long-term strategic partnership with the largest airline in the country, LATAM.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.